Graphite India
ICICI Securities Limited
Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
---|---|---|---|---|---|---|---|---|---|---|---|
13 Aug 2019 | Graphite |
ICICI Securities Limited
|
563.25 | 275.00 | 292.00 (92.89%) | Target met |
Sell
|
||||
12 Aug 2019 | Cummins |
Karvy
|
3966.00 | 592.00 | 594.70 (566.89%) | Target met |
Sell
|
Cummins India Ltd: Dismal Q1 from Cummins; Management Trims Guidance
Karvy
Cummins Q1 earnings came in below our estimates primarily on account of lower exports impacting operating margin by 1.5 percent and Fx impacting 1percentof operating margin.
|
|||
12 Aug 2019 | Bharat Petroleum |
Reliance Securities
|
338.70 | 330.00 | 346.45 (-2.24%) | Target met |
Sell
|
BPCL - 1QFY20 Result Update
Reliance Securities
Despite good performance in marketing segment, Bharat Petroleum Corporation (BPCL) has reported weak operating performance in 1QFY20 with EBITDA falling by 44% YoY and 55% QoQ to Rs21.8bn (in line with our estimate) led by lower refining throughput and margin. It reported a GRM of US$2.81/bbl in 1QFY20 vs. US$7.49/bbl in1QFY19. We believe 4% YoY fall in crude throughput was mainly due to Mumbai refinery upgradation for BS-VI fuel. Its net profit declined by 53% YoY and 66% QoQ to Rs10.7bn (11% above our estimate) mainly due to higher interest cost (+50% YoY and +28% QoQ). Notably, its debt increased by Rs15.5bn sequentially. Further, adoption of Ind AS-116 resulted into net Rs520mn decrease in PBT. In Jul'19, benchmark complex...
|
|||
11 Aug 2019 | Divi's Laboratories |
HDFC Securities
|
6474.50 | 1320.00 | 1664.95 (288.87%) |
Sell
|
Divi's Labs (1QFY20): Overpriced. Maintain SELL
HDFC Securities
We had downgraded Divi's after it reported one of its strongest quarters in a decade in 2QFY19, as we had realized that the performance was driven by shortages in certain molecules (like Valsartan) and currency erosion of ~10% during that quarter. For the last 2 quarters, our thesis of margin contraction is playing out and we have further cut our FY20/21E estimates by 8-9% as we are yet to see the impact of ongoing capex. We believe it would be a challenging task for Divi's to cross 36-37% margin in FY20/21E. Still, with our generous estimates of 11/10/11% revenue/EBITDA/PAT CAGR over FY20-21E, Divi's is trading at 32.3/27.7x FY20/21E EPS, a ~50% premium to peer-avg and ~40% above its historical avg, much of which corresponds to periods of 40% plus return ratios. Even so, valuations have rarely crossed 25x one-year forward P/E. With return ratios falling below 20%, current valuations look unsustainable. We maintain SELL on DIVI, following a second consecutive quarter of dismal performance. With sustained erosion in profitability, we have cut our FY20/21E EPS estimates by 8-9%. At 22x FY21E EPS, our revised TP is at Rs 1,320.
|
||||
09 Aug 2019 | Tech Mahindra |
BOB Capital Markets Ltd.
|
1457.20 | 660.00 | 663.35 (119.67%) | Target met |
Sell
|
Tech Mahindra (REDUCE): Subsidiary troubles afresh; cut to REDUCE
BOB Capital Markets Ltd.
Tech Mahindra (TECHM) subsidiary Pininfarina (PINF) was a harbinger of growth for the company over the past two years, bringing in 16% of incremental FY19 revenue.
|
|||
08 Aug 2019 | Tata Consumer |
Karvy
|
1126.50 | 263.00 | 267.00 (321.91%) | Target met |
Sell
|
||||
08 Aug 2019 | Hindustan Petroleum |
BOB Capital Markets Ltd.
|
452.50 | 200.00 | 250.40 (80.71%) | Target met |
Sell
|
||||
08 Aug 2019 | Tata Steel |
Prabhudas Lilladhar
|
173.86 | 350.00 | 367.40 (-52.68%) | Target met |
Sell
|
Q1FY20 Result Update
Prabhudas Lilladhar
fall in EBITDA at US$9mn (PLe:USD$125mn). Operational issues and sharp fall in spreads impacted TSE's earnings. Due to weak margins in TSE, we cut our EBITDA/EPS estimates for FY20E by 4%/18%. Despite sharp increase in iron ore prices, steel prices softened by US$20-25/t in last couple of months. In spite of serious trade restrictions imposed on its imports by various countries, China acted in a disciplined manner with reduced export intensity and stable domestic demand. On the contrary, RoW (ex-China), the so called disciplined and earnings focused markets witnessed...
|
|||
08 Aug 2019 | Lupin |
Prabhudas Lilladhar
|
1959.30 | 730.00 | 760.95 (157.48%) | Target met |
Sell
|
Q1FY20 Result Update
Prabhudas Lilladhar
With benefits from the last quarter of exclusive sales of gRanexa and slower Change in Estimates | Target | Reco ramp up in Levothyroxyn sales, the adj. sales increased by by 1% QoQ due to muted growth in Japan and declining sales in US (constant currency). Adj....
|
|||
08 Aug 2019 | Lupin |
Reliance Securities
|
1959.30 | 715.00 | 760.95 (157.48%) | Target met |
Sell
|
Lupin - 1QFY20 Result Update
Reliance Securities
Currently, LPC has OAI status for its 4 plants i.e. (1) Mandideep Unit 1 (No new approval pending for approval); (2) Goa (30-40% of US sales; WL also; 20 pending ANDAs); (3) Somerset (~15-20% to US sales, ~40 ANDA pending ANDAs); (4) Pithampur Unit 2 (WL; 15-20 ANDAs pending for approvals; no new filings since WL). We expect the pending US FDA issues to remain as the key overhang for the...
|
|||
more
loading
|